Abstract:The market for direct-to-consumer (DTC) health services continues to grow rapidly with former patients converting to customers for the opportunity to purchase varied diagnostic tests without the involvement of their clinician. For the first time a DTC genetic testing company is advertising health-related reports "that meet [Food and Drug Administration] standards for being clinically and scientifically valid." Ethicists and regulatory agencies alike have recognized the need for a more informed transaction in the DTC context, but how should we classify a commercial transaction for something normally protected by a duty of care? How can we assure informed agreements in an industry with terms and conditions as varied as the services performed? The doctrine of "informed consent" began as an ethical construct building on the promise of beneficence in the clinical relationship and elevating the principle of autonomy--but in the DTC context should we hold providers to legal standards of informed consent and associated medical malpractice liability, or contractual obligations where consumers would seek remedy for breach? This Article analyzes the fine balance that must be struck in an industry where companies are selling services for entertainment or non-medical purposes that possess the capacity to produce serious and disquieting medical information. It begins by reviewing current standards of consent in the clinical setting from both a legal and ethical perspective and then lays forth current standards for DTC consent using two currently controversial case studies: that of keepsake fetal ultrasound and genetic testing. DTC keepsake ultrasound and genetic testing providers attempt to de-medicalize the devices used for these procedures from their intended medical uses to non-medical uses. But while keepsake ultrasound is marketed as "intended for entertainment purposes only," it can provide medical information as an incidental finding. 23andMe currently purports to be the only DTC genetics service that "includes" reports that meet FDA qualifications, despite disclaimers of intent to "provide medical advice." The attempted de-medicalization of these devices, therefore, has not been fully transformative, and DTC providers should have more robust ethical and legal duties than the average goods and services seller. This Article delineates these responsibilities, beginning with ethical duties surrounding marketing, entering into, and providing DTC services. It then turns to the legal paradigms necessary to enable, or at least allow for, DTC providers to meet these ethical obligations. While it argues that contractual, as opposed to fiduciary, requirements are most appropriate and that waivers of liability will likely be upheld, it also advocates for a heightened expectation of disclosure during contracting.

[Direct-to-consumer genetic testing: a regulation by the market, or a medical regulation?]

[Direct-to-consumer genetic tests in the Netherlands: impact on consumers and clinical practice]

Policy Guidance for Direct-to-Consumer Genetic Testing Services: Framework Development Study

Foreign Experience in the Legal Regulation of Direct Consumer Genetic Testing

RECONCEPTUALIZING CONSENT FOR DIRECT-TO-CONSUMER HEALTH SERVICES

Economic regulation of next-generation sequencing

Genetic and Genomic Consultation: Are We Ready for Direct-to-Consumer Telegenetics?

Regulating molecular diagnostic assays: developing a new regulatory structure for a new technology

Public Perspectives on Direct-to-Consumer Testing Oversight

Direct-to-Consumer Genetic Tests and Canadian Genetic Counselors: A Pilot Exploration of Professional Roles in Response to Novel Biotechnologies

Genetic Privacy and Data Protection: A Review of Chinese Direct-to-Consumer Genetic Test Services

Changes in acceptability, consideration, intention, and uptake of direct‐to‐consumer genetic tests in the Netherlands from 2017 to 2022

Direct-to-consumer genetic testing in the news: a descriptive analysis

Direct-to-consumer genetic testing and the changing landscape of gamete donor conception: key issues for practitioners and stakeholders

Neither as harmful as feared by critics nor as empowering as promised by providers: risk information offered direct to consumer by personal genomics companies

Community-led risk analysis of direct-to-consumer whole-genome sequencing

Types of genetic determinism in direct-to-consumer genetic testing for health

Regulating Direct-to-Consumer Polygenic Risk Scores

The Landscape of Direct-To-Consumer Genetic Testing in Reproductive Health Contexts: An Analytical Framework of Stakeholders and Their Competing Motivations

An analysis of direct-to-consumer genetic testing portals and their communication of health risk and test limitations

Importance of Effective Regulation for the Chinese Genetic Testing Industry